Table II.
Characteristics of all study patients and stratified by presence of acute rejection (AR) in the first six months post-transplant.
| ALL (N=1930) | Subjects AR free during first 6 months (N=1779) | Subjects with AR during first 6 months (N=151) | |
|---|---|---|---|
| Age of recipient in years mean (SD) | 50(13.3) | 50(13.3) | 48.4(13.7) |
| Male recipient | 1217(63.1%) | 1111(62.4%) | 106(70.2%) |
| African American recipient | 353(18.3%) | 335(18.8%) | 18(11.9%) |
| BMI mean (SD) | 28 (5.5) | 28.2(5.5) | 27.9(6.0) |
| Simultaneous kidney-pancreas transplant | 157(8.1%) | 134(7.5%) | 23 (15.2%) |
| Diabetes pre-transplant | 753 (39%) | 696 (39%) | 57 (38%) |
| Immune related factors | |||
| HLA mismatch | |||
| None | 224(11.6%) | 218(12.3%) | 6(3.97%) |
| 1 or 2 | 297(15.4%) | 277(15.6%) | 20(13.3%) |
| 3 or 4 | 754(39.1%) | 695(39.1%) | 59(39.1%) |
| 5 or 6 | 653(33.9%) | 587(33.0%) | 66(43.7%) |
| Panel reactive antibody positive | 952(49.5%) | 859(48.4%) | 93(61.6%) |
| Positive T or B cell cross match | 138(7.2%) | 113(6.4%) | 25(16.7%) |
| Prior solid organ transplant | 504 (26.1%) | 444 (25.0%) | 60 (39.7%) |
| Prior kidney transplant | 302 (15.6%) | 265 (14.9%) | 37 (24.5%) |
| Donor related factors | |||
| Age of donor in years mean (SD) | 40.8(14) | 40.6(14) | 42.8(13.7) |
| Deceased donor | 816(42.%) | 754(42.4%) | 62(41.1%) |
| Immunosuppression | |||
| Induction regimen | |||
| Monoclonal antibody | 782(40.5%) | 747(42.0%) | 35(23.2%) |
| Polyclonal antibody | 1026(53.2%) | 928(52.2%) | 98(64.9%) |
| Combination | 49(2.5%) | 39(2.2%) | 10(6.6%) |
| None | 73(3.8%) | 65(3.7%) | 8(5.3%) |
| Steroid free by 7 days post-transplant | 722(37.45%) | 668(37.6%) | 54(36.0%) |
| Use of mycophenolate in first 6 monthsl | 1597(99.3%) | 1463(99.2%) | 134(100.0%) |
| Use of mTOR inhibitors | 3(0.2%) | 2(0.1%) | 1(0.8%) |
| Median TAC trough, ng/mL immediately proximal to AR event median (Interquartile range) | N/A | N/A | 7.6(4.8–9.9) |